Recent News

• 08.03.2026 - Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
• 07.23.2026 - Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
• 05.18.2026 - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
• 05.07.2026 - Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
• 05.04.2026 - Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
• 04.30.2026 - Krystal Biotech to Present at Upcoming Scientific Conferences
• 04.21.2026 - Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
• 02.24.2026 - Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
• 02.17.2026 - Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
• 02.10.2026 - Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Recent Filings

• 08.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.03.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 8-K Current report
• 07.21.2026 - 8-K Current report
• 07.21.2026 - EX-99.1 EX-99.1
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 144 Report of proposed sale of securities
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 144 Report of proposed sale of securities